Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Marinus Pharmaceuticals
Pharma
Marinus trims workforce by 45% after pair of clinical stumbles
The company last month opted to end development of its flagship seizure drug while exploring "strategic alternatives" to maximize shareholder value.
Zoey Becker
Nov 13, 2024 11:26am
Marinus to end further Ztalmy development after another trial miss
Oct 24, 2024 12:30pm
With investor lawsuit and trial flop, troubles mount for Marinus
Jun 17, 2024 4:33pm
Marinus seizure med fails at interim analysis; shares plummet
Apr 15, 2024 12:31pm
HHS taps Marinus Pharma to produce API for anti-seizure drug
Sep 22, 2022 9:40am
Marinus starts marketing voyage for kids epilepsy med Ztalmy
Aug 2, 2022 9:50am
